Vineet Laboratories Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Vineet Laboratories's earnings have been declining at an average annual rate of -3.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 31.9% per year. Vineet Laboratories's return on equity is 0.4%, and it has net margins of 0.1%.
Belangrijke informatie
-3.1%
Groei van de winst
-1.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | -31.9% |
| Rendement op eigen vermogen | 0.4% |
| Nettomarge | 0.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt
Jul 12
Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive
Mar 07We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt
Feb 15With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case
Nov 14Opbrengsten en kosten
Hoe Vineet Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,369 | 1 | 65 | 0 |
| 31 Mar 24 | 1,510 | 10 | 65 | 0 |
| 31 Dec 23 | 1,707 | 27 | 62 | 0 |
| 30 Sep 23 | 2,049 | 61 | 64 | 0 |
| 30 Jun 23 | 2,010 | -10 | 62 | 0 |
| 31 Mar 23 | 2,123 | 13 | 61 | 0 |
| 31 Dec 22 | 2,107 | 10 | 56 | 0 |
| 30 Sep 22 | 1,823 | 10 | 47 | 0 |
| 30 Jun 22 | 1,823 | 64 | 46 | 0 |
| 31 Mar 22 | 1,912 | 66 | 58 | 0 |
| 31 Mar 21 | 2,435 | 18 | 56 | 0 |
Kwaliteitswinsten: VINEETLAB has high quality earnings.
Groeiende winstmarge: VINEETLAB became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VINEETLAB's earnings have declined by 3.1% per year over the past 5 years.
Versnelling van de groei: VINEETLAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: VINEETLAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Rendement op eigen vermogen
Hoge ROE: VINEETLAB's Return on Equity (0.4%) is considered low.